Wire · opportunities
FDA clears blood test to aid evaluation for Alzheimer's disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 August 2026 · Fusion42 review
The FDA has cleared PrecivityAD2, a blood-based test developed by C2N Diagnostics and Washington University, to aid in identifying brain amyloid plaques associated with Alzheimer's disease. This test offers a less invasive diagnostic method compared to cerebrospinal fluid testing and supports earlier treatment of Alzheimer’s disease.
This Wire brief sits within Fusion42's coverage of Digital Health, and 13 sources have reported it between 20 Aug 2026 and 26 Sep 2026.
◆ ◆ The Wire takeaway
You face a new way to diagnose Alzheimer’s with less invasive testing that can hasten patient treatment starts. Clinicians and health systems now have FDA-backed tools that could shift how you market and position diagnostics for cognitive decline.
◆ Coverage
13 sources · first reported 20 Aug 2026 · latest 26 Sep 2026
◆ Related on Wire
◆ Topics